Christopher J. Schaber

About Christopher J. Schaber

Christopher J. Schaber, PhD is a seasoned executive and entrepreneur with over 35 years of experience in the pharmaceutical and biotechnology industry. He has a proven track record of advancing novel therapies from discovery to approval, as well as securing funding and partnerships to support the growth and vision of the start-up companies he has co-founded and/or led. In his current position as Chairman, President and CEO of Soligenix, Inc, he leads a team of dedicated professionals who are committed to developing and commercializing products for rare diseases with high unmet medical need. Dr. Schaber is a recognized leader and influencer in the rare disease community, serving on the boards and councils of various organizations, such as the Alliance for Biosecurity, BioNJ, and the National Organization for Rare Disorders (NORD). He is also an active advisor, board member, mentor, and investor in the life sciences and technology sectors, supporting the growth and development of emerging companies and entrepreneurs. In addition, he contributes his time serving on a number of advisory councils for regional universities, including Rutgers, Rowan, Stevens and Temple, assisting faculty with advancing the technology coming out of their laboratories, as well as educating the next generation of entrepreneurs and leaders in start-up business. Dr. Schaber holds a PhD in Pharmaceutical Sciences, a MS in Pharmaceutics, and undergraduate degrees in Business and Economics.

Experience

1. Corporate Council Member

   National Organization for Rare Disorders

   Jun 2011 — Present · Washington, DC, US

Skills

• Regulatory Submissions
• Drug Discovery
• Mergers & Acquisitions
• Start-Ups
• Clinical Data Management
• Strategy
• Biotechnology
• Corporate Development
• Development Strategy
• Gmp
• Cmc
• Clinical Development
• Biopharmaceuticals
• Drug Delivery
• Validation
• Oncology
• CRO
• Commercialization
• Pharmacology
• Fda
• Strategic Planning